Home > Market > Market Stats >  Abbott India

Abbott India

Sector: Biotechnology & Drugs
Powered by
19030.60 -157.35 (-0.82%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 18812.0
Today’s High 19285.0
52 Week Low 15426.74
52 Week High 23751.02

Key Metrics

  • Market Cap (In Cr) 40758.5
  • Beta 0.2
  • Div. Yield (%) 0.76
  • P/B 14.45
  • TTM P/E 48.99
  • Peg Ratio 3.74
  • Sector P/E 24.66
  • D/E -
  • Open Price 18906.05
  • Prev Close 19187.95
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    7.11%
  • 3 Months
    2.89%
  • 6 Month
    9.04%
  • YTD
    -0.94%
  • 1 Year
    -1.29%
Risk Meter
  • 25% Low risk
  • 25% Moderate risk
  • 25% Balanced Risk
  • 25% High risk
  • 25% Extreme risk
Recos
9 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 2
  • Sell
  • 0
  • Hold
  • 2
  • Buy
  • 1
  • Strong Buy
  • 4

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 4919.27
  • Selling/ General/ Admin Expenses Total
  • 1086.89
  • Depreciation/ Amortization
  • 66.1
  • Other Operating Expenses Total
  • 57.26
  • Total Operating Expense
  • 3892.34
  • Operating Income
  • 1026.93
  • Net Income Before Taxes
  • 1079.73
  • Net Income
  • 798.7
  • Diluted Normalized EPS
  • 375.87
  • Period
  • 2021
  • Total Revenue
  • 4310.02
  • Selling/ General/ Admin Expenses Total
  • 918.82
  • Depreciation/ Amortization
  • 58.13
  • Other Operating Expenses Total
  • 53.77
  • Total Operating Expense
  • 3441.5
  • Operating Income
  • 868.52
  • Net Income Before Taxes
  • 925.95
  • Net Income
  • 690.69
  • Diluted Normalized EPS
  • 325.12
  • Period
  • 2020
  • Total Revenue
  • 4093.14
  • Selling/ General/ Admin Expenses Total
  • 929.42
  • Depreciation/ Amortization
  • 59.61
  • Other Operating Expenses Total
  • 59.3
  • Total Operating Expense
  • 3386.48
  • Operating Income
  • 706.66
  • Net Income Before Taxes
  • 802.69
  • Net Income
  • 592.93
  • Diluted Normalized EPS
  • 279.22
  • Period
  • 2019
  • Total Revenue
  • 3678.6
  • Selling/ General/ Admin Expenses Total
  • 914.55
  • Depreciation/ Amortization
  • 16.92
  • Other Operating Expenses Total
  • 47
  • Total Operating Expense
  • 3085.21
  • Operating Income
  • 593.4
  • Net Income Before Taxes
  • 698.85
  • Net Income
  • 450.33
  • Diluted Normalized EPS
  • 209
  • Period
  • 2018
  • Total Revenue
  • 3307.12
  • Selling/ General/ Admin Expenses Total
  • 802.68
  • Depreciation/ Amortization
  • 16.19
  • Other Operating Expenses Total
  • 46.66
  • Total Operating Expense
  • 2793.21
  • Operating Income
  • 513.91
  • Net Income Before Taxes
  • 621.48
  • Net Income
  • 401.22
  • Diluted Normalized EPS
  • 175.14
  • Period
  • 2017
  • Total Revenue
  • 2938.69
  • Selling/ General/ Admin Expenses Total
  • 717.7
  • Depreciation/ Amortization
  • 16.43
  • Other Operating Expenses Total
  • 56.1
  • Total Operating Expense
  • 2552.78
  • Operating Income
  • 385.91
  • Net Income Before Taxes
  • 436.49
  • Net Income
  • 276.65
  • Diluted Normalized EPS
  • 130.25
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day18427.61
  • 10 Day18131.72
  • 20 Day18097.31
  • 50 Day18881.54
  • 100 Day18503.84
  • 300 Day17893.1

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • Abbott India
  • 19030.6
  • -157.35
  • -0.82
  • 23751.02
  • 15426.74
  • 40758.5

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 10-Aug-22
  • Quarterly Results
  • 17-May-22
  • Audited Results & Dividend
  • 09-Feb-22
  • Quarterly Results
  • 12-Nov-21
  • Quarterly Results
  • 06-Aug-21
  • Quarterly Results
  • 18-May-21
  • Audited Results & Final Dividend
  • 09-Feb-21
  • Quarterly Results

Company Profile

ABOUT Abbott India

  • Industry Biotechnology & Drugs
  • ISIN INE358A01014
  • BSE Code 500488
  • NSE Code ABBOTINDIA

Abbott India Limited is an India-based company that is engaged in pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines and consumer health, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremalax (constipation), Pankreoflat (indigestion) and Duvadilan (preterm labor), among others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure and Glucerna, among others.

MANAGEMENT

  • Sridhar Kadangode Director - Finance
  • Krupa Anandpara Compliance Officer, Associate Director - Secretarial & Company Secretary
  • Vivek Kamath Managing Director, Additional Director
  • Kunal Chowdhury Commercial Director - GI Business
  • Prateek Gupta Director - Commercial Excellence
  • Rajan Kalantre Director - Business Human Resources
  • Jejoe Karankumar Director - Medical Affairs
  • Shantaprasad Nagarmath Commercial Director – Gennext, Vaccines and Consumer Health
  • T. Prasad Commercial Director - Specialty Care
  • Sandeep Reddy Associate Director - Women’s Health

Company Summary

ABBOTT INDIA SUMMARY

Abbott India is trading 0.82% lower at Rs 19030.60 as compared to its last closing price. Abbott India has been trading in the price range of 19285.0 & 18812.0. Abbott India has given -0.94% in this year & 7.11% in the last 5 days.

 

Abbott India has TTM P/E ratio 48.99 as compared to the sector P/E of 24.66. There are 9 analysts who have initiated coverage on Abbott India. There are 4 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

 

The company posted a net profit of 205.64 Crores in its last quarter.

 

Listed peers of Abbott India include Dr Reddys Laboratories (-0.58%), Torrent Pharmaceuticals (0.28%), Abbott India (-0.82%) etc.

FAQs about Abbott India

Abbott India is trading at 19030.60 as on 30 Sep, 2022 3:29:46 PM. This is -0.82% lower as compared to its previous closing price of 19187.95
The market capitalization of Abbott India is 40758.5 Cr as on 30 Sep, 2022 3:29:46 PM.
The average broker rating on Abbott India is Buy. The breakup of analyst rating is given below -
  • 2 analysts have given a strong sell rating
  • 0 analysts have given a sell rating
  • 2 analysts have given a hold rating
  • 1 analysts have given a buy rating
  • 4 analysts have given a strong buy rating
The 52 wk high for Abbott India is 23751.02 whereas the 52 wk low is 15426.74
Abbott India can be analyzed on the following key metrics -
  • TTM P/E: 48.99
  • Sector P/E: 24.66
  • Dividend Yield: 0.76%
  • D/E ratio: -
Abbott India reported a net profit of 798.7 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout